Blood carnitine profiling on tandem mass spectrometry in liver cirrhotic patients.
Acylcarnitine
Carnitine fraction
Liver cirrhosis
Tandem mass spectrometry
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
19 Feb 2020
19 Feb 2020
Historique:
received:
27
09
2019
accepted:
11
02
2020
entrez:
21
2
2020
pubmed:
23
2
2020
medline:
15
12
2020
Statut:
epublish
Résumé
The level and profiles of blood free carnitine and acylcarnitines, obtained by acylcarnitine analysis using tandem mass spectrometry, reflect various metabolic conditions. We aimed to examine the level of free carnitine and acylcarnitines in liver cirrhosis patients by acylcarnitine analysis and determine the clinical and subjective factors associated with blood carnitine fraction levels in liver cirrhosis. We compared blood carnitine fractions in 54 liver cirrhotic patients to other laboratory test results and questionnaire answers. In almost all patients, the blood levels of free carnitine (C0) and acetylcarnitine (C2) were within the normal reference range. However, in some patients, the levels of long-chain acylcarnitines, such as C16 and C18:1-acylcarnitine, were higher than the normal reference range. Liver function, assessed by Child-Pugh score, was significantly correlated with the blood level of each carnitine fraction measured (C0, C2, C3, C4, C6, C10, C12, C12:1, C14:1, C16, C18:1, and C18:2-acylcarnitine). Cirrhotic symptom score was significantly correlated with C0, C2, C3, C16, and C18-1-acylcarnitine blood levels. Among the 36-item short-form health survey (SF-36) items, the physical component summary was significantly associated with C0, C2, and C18-1-acylcarnitine blood levels. Carnitine fraction levels were positively correlated with liver cirrhosis stage, particularly, long-chain acylcarnitines. Moreover, carnitine fraction levels were associated with various subjective physical symptoms in liver cirrhosis patients.
Sections du résumé
BACKGROUND
BACKGROUND
The level and profiles of blood free carnitine and acylcarnitines, obtained by acylcarnitine analysis using tandem mass spectrometry, reflect various metabolic conditions. We aimed to examine the level of free carnitine and acylcarnitines in liver cirrhosis patients by acylcarnitine analysis and determine the clinical and subjective factors associated with blood carnitine fraction levels in liver cirrhosis.
METHODS
METHODS
We compared blood carnitine fractions in 54 liver cirrhotic patients to other laboratory test results and questionnaire answers.
RESULTS
RESULTS
In almost all patients, the blood levels of free carnitine (C0) and acetylcarnitine (C2) were within the normal reference range. However, in some patients, the levels of long-chain acylcarnitines, such as C16 and C18:1-acylcarnitine, were higher than the normal reference range. Liver function, assessed by Child-Pugh score, was significantly correlated with the blood level of each carnitine fraction measured (C0, C2, C3, C4, C6, C10, C12, C12:1, C14:1, C16, C18:1, and C18:2-acylcarnitine). Cirrhotic symptom score was significantly correlated with C0, C2, C3, C16, and C18-1-acylcarnitine blood levels. Among the 36-item short-form health survey (SF-36) items, the physical component summary was significantly associated with C0, C2, and C18-1-acylcarnitine blood levels.
CONCLUSIONS
CONCLUSIONS
Carnitine fraction levels were positively correlated with liver cirrhosis stage, particularly, long-chain acylcarnitines. Moreover, carnitine fraction levels were associated with various subjective physical symptoms in liver cirrhosis patients.
Identifiants
pubmed: 32075591
doi: 10.1186/s12876-020-01190-6
pii: 10.1186/s12876-020-01190-6
pmc: PMC7029602
doi:
Substances chimiques
acylcarnitine
0
Carnitine
S7UI8SM58A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Références
Clin Gastroenterol Hepatol. 2015 Aug;13(8):1540-3
pubmed: 25496816
Am J Physiol. 1980 May;238(5):E409-15
pubmed: 7377339
Dig Dis. 2003;21(3):271-5
pubmed: 14571103
World J Gastroenterol. 2005 Dec 7;11(45):7197-202
pubmed: 16437672
J Clin Invest. 1981 Jul;68(1):240-52
pubmed: 7251861
Psychiatry Res. 2000 Dec 27;97(2-3):165-72
pubmed: 11166088
Am J Physiol. 1978 May;234(5):E494-9
pubmed: 645901
Hepatol Res. 2017 Mar;47(4):321-327
pubmed: 27254133
Anal Bioanal Chem. 2012 Apr;403(1):203-13
pubmed: 22349331
Obesity (Silver Spring). 2010 Sep;18(9):1695-700
pubmed: 20111019
Adv Lipid Res. 1963;1:285-334
pubmed: 14248955
Biochem Mol Biol Int. 1998 Jan;44(1):185-93
pubmed: 9503162
PLoS One. 2018 Aug 22;13(8):e0201591
pubmed: 30133480
Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):77-85
pubmed: 16602102
Nutr Metab (Lond). 2010 Apr 16;7:30
pubmed: 20398344
Biomed Rep. 2016 Aug;5(2):193-198
pubmed: 27446540
Nutrition. 1993 May-Jun;9(3):246-54
pubmed: 8353366
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Biochem J. 1996 Dec 1;320 ( Pt 2):345-57
pubmed: 8973539